Profit and Loss Results Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is 175.71% vs 27.93% in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is -2.56% vs -36.25% in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 11.78% vs 7.15% in Mar 2024
Profit After Tax
YoY Growth in year ended Mar 2025 is -178.29% vs 69.93% in Mar 2024
Compare Profit and Loss Results of Oxygenta Pharma
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
109.00
115.00
-6.00
-5.22%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
109.00
115.00
-6.00
-5.22%
Expenditure (Ex Depriciation)
Stock Adjustments
-3.00
3.00
-6.00
-200.00%
Raw Materials Consumed
100.00
49.00
51.00
104.08%
Power & Fuel Cost
6.00
3.00
3.00
100.00%
Employee Cost
6.00
14.00
-8.00
-57.14%
Operating Expenses
5.00
4.00
1.00
25.00%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
0.00
2.00
-2.00
-100.00%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
0.00
5.00
-5.00
-100.00%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
119.00
88.00
31.00
35.23%
Operating Profit (PBDIT) excl Other Income
-9.00
26.00
-35.00
-134.62%
Other Income
1.00
9.00
-8.00
-88.89%
Operating Profit (PBDIT)
-8.00
35.00
-43.00
-122.86%
Interest
1.00
0.00
1.00
0%
Profit before Depriciation and Tax
-10.00
35.00
-45.00
-128.57%
Depreciation
0.00
2.00
-2.00
-100.00%
Profit Before Taxation & Exceptional Items
-11.00
33.00
-44.00
-133.33%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
-11.00
32.00
-43.00
-134.38%
Provision for Tax
-1.00
8.00
-9.00
-112.50%
Profit After Tax
-9.00
24.00
-33.00
-137.50%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
-63.00
147.00
-210.00
-142.86%
Profit Available for appropriations
-73.00
171.00
-244.00
-142.69%
Appropriations
-73.00
171.00
-244.00
-142.69%
Equity Dividend (%)
0%
0%
0.00
Earnings Per Share
-2.69
67.61
-70.30
-103.98%
Profit And Loss - Net Sales
Net Sales 109.30 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 175.71% vs 27.93% in Mar 2024
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) -9.94 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -2.56% vs -36.25% in Mar 2024
Profit And Loss - Interest
Interest 1.78 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 11.78% vs 7.15% in Mar 2024
Profit And Loss - Profit After Tax
Profit After Tax -9.68 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -178.29% vs 69.93% in Mar 2024
